196 related articles for article (PubMed ID: 21352693)
1. Oncogene interactions are required for glioma development and progression as revealed by a tissue specific transgenic mouse model.
Moore LM; Holmes KM; Fuller GN; Zhang W
Chin J Cancer; 2011 Mar; 30(3):163-72. PubMed ID: 21352693
[TBL] [Abstract][Full Text] [Related]
2. Development of a Sox2 reporter system modeling cellular heterogeneity in glioma.
Stoltz K; Sinyuk M; Hale JS; Wu Q; Otvos B; Walker K; Vasanji A; Rich JN; Hjelmeland AB; Lathia JD
Neuro Oncol; 2015 Mar; 17(3):361-71. PubMed ID: 25416826
[TBL] [Abstract][Full Text] [Related]
3. RCAS-TVA in the mammary gland: an in vivo oncogene screen and a high fidelity model for breast transformation?
Du Z; Li Y
Cell Cycle; 2007 Apr; 6(7):823-6. PubMed ID: 17377492
[TBL] [Abstract][Full Text] [Related]
4. The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer.
Lewis BC; Klimstra DS; Varmus HE
Genes Dev; 2003 Dec; 17(24):3127-38. PubMed ID: 14681205
[TBL] [Abstract][Full Text] [Related]
5. Genetically engineered mouse models of brain cancer and the promise of preclinical testing.
Huse JT; Holland EC
Brain Pathol; 2009 Jan; 19(1):132-43. PubMed ID: 19076778
[TBL] [Abstract][Full Text] [Related]
6. Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma.
McKinney AJ; Holmen SL
Chin J Cancer; 2011 Mar; 30(3):153-62. PubMed ID: 21352692
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network.
Holmes KM; Annala M; Chua CY; Dunlap SM; Liu Y; Hugen N; Moore LM; Cogdell D; Hu L; Nykter M; Hess K; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2012 Feb; 109(9):3475-80. PubMed ID: 22345562
[TBL] [Abstract][Full Text] [Related]
8. Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance.
Pao W; Klimstra DS; Fisher GH; Varmus HE
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8764-9. PubMed ID: 12857957
[TBL] [Abstract][Full Text] [Related]
9. Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies.
de Vries NA; Bruggeman SW; Hulsman D; de Vries HI; Zevenhoven J; Buckle T; Hamans BC; Leenders WP; Beijnen JH; van Lohuizen M; Berns AJ; van Tellingen O
Clin Cancer Res; 2010 Jul; 16(13):3431-41. PubMed ID: 20472681
[TBL] [Abstract][Full Text] [Related]
10. A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors.
Seidler B; Schmidt A; Mayr U; Nakhai H; Schmid RM; Schneider G; Saur D
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10137-42. PubMed ID: 18621715
[TBL] [Abstract][Full Text] [Related]
11. Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies.
Phillips LM; Zhou X; Cogdell DE; Chua CY; Huisinga A; R Hess K; Fuller GN; Zhang W
J Pathol; 2016 Jul; 239(3):355-64. PubMed ID: 27125842
[TBL] [Abstract][Full Text] [Related]
12. Applications of mouse glioma models in preclinical trials.
Hu X; Holland EC
Mutat Res; 2005 Aug; 576(1-2):54-65. PubMed ID: 16011838
[TBL] [Abstract][Full Text] [Related]
13. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Turner KM; Sun Y; Ji P; Granberg KJ; Bernard B; Hu L; Cogdell DE; Zhou X; Yli-Harja O; Nykter M; Shmulevich I; Yung WK; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3421-6. PubMed ID: 25737557
[TBL] [Abstract][Full Text] [Related]
14. Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma.
Lindberg N; Kastemar M; Olofsson T; Smits A; Uhrbom L
Oncogene; 2009 Jun; 28(23):2266-75. PubMed ID: 19421151
[TBL] [Abstract][Full Text] [Related]
15. Mouse models for cancer research.
Zhang W; Moore L; Ji P
Chin J Cancer; 2011 Mar; 30(3):149-52. PubMed ID: 21352691
[TBL] [Abstract][Full Text] [Related]
16. Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis.
Ji P; Zhou X; Liu Q; Fuller GN; Phillips LM; Zhang W
Oncotarget; 2016 Apr; 7(17):23521-9. PubMed ID: 26993778
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy and targeted toxins for glioma.
King GD; Curtin JF; Candolfi M; Kroeger K; Lowenstein PR; Castro MG
Curr Gene Ther; 2005 Dec; 5(6):535-57. PubMed ID: 16457645
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of new transgenic mouse models in glioma research.
Sonabend AM; Ulasov IV; Lesniak MS
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S7-13. PubMed ID: 18076321
[TBL] [Abstract][Full Text] [Related]
19. RCAS/SCL-TVA animal model allows targeted delivery of polyoma middle T oncogene to vascular endothelial progenitors in vivo and results in hemangioma development.
Sausville J; Molinolo AA; Cheng X; Frampton J; Takebe N; Gutkind JS; Feldman RA
Clin Cancer Res; 2008 Jun; 14(12):3948-55. PubMed ID: 18559617
[TBL] [Abstract][Full Text] [Related]
20. Review: insights gained from modelling high-grade glioma in the mouse.
Rankin SL; Zhu G; Baker SJ
Neuropathol Appl Neurobiol; 2012 Jun; 38(3):254-70. PubMed ID: 22035336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
